Endomorphins (EMs), two endogenous l-opioid receptor selective ligands, are attractive lead compounds for opioid-based pain management studies. However, these peptides are quickly degraded by peptidases, in particular by dipeptidylpeptidase IV (DPP IV) and aminopeptidase M (APM). Targeting enzymatic degradation is one approach to prolong endomorphin activity. In this study we characterized the action of two new inhibitors of similar to endomorphins structure, Tyr-Pro-Ala-NH 2 (EMDB-2) and Tyr-Pro-Ala-OH (EMDB-3), which were designed earlier in our laboratory. The presented data give evidence that EMDB-2 and EMDB-3 are potent inhibitors of enzymes responsible for endomorphin cleavage. These compounds are stable and easily synthesized. EMDB-2 and EMDB-3 are competitive inhibitors of both, DPP IV and APM, with K i values in micromolar range. They are less potent than diprotin A in protecting EMs against DPP IV but more potent than actinonin in protecting these peptides against APM. © Springer Science+Business Media, LLC 2011.
CITATION STYLE
Perlikowska, R., Fichna, J., Do-Rego, J. C., Gach, K., & Janecka, A. (2012). Kinetic studies of novel inhibitors of endomorphin degrading enzymes. Medicinal Chemistry Research, 21(7), 1445–1450. https://doi.org/10.1007/s00044-011-9666-5
Mendeley helps you to discover research relevant for your work.